Johnson Matthey partners with Immunomedics to develop life-saving cancer treatment
09 January 2019
Johnson Matthey (LSE: JMAT), a global leader in science that enables a cleaner and healthier world, today announced a strategic manufacturing partnership for the large-scale production of the drug-linker used in Immunomedics鈥� lead antibody-drug conjugate.
The antibody-drug conjugate, sacituzumab govitecan, is a treatment for patients with metastatic triple-negative breast cancer, currently under priority review by the FDA for accelerated approval. If approved, sacituzumab govitecan would be the first therapy approved for this patient group.
The drug-linker CL2A-SN-38 is a critical component in the novel antibody-drug conjugate. This key constituent is being produced at JM鈥檚 Devens, MA facility. Immunomedics has significantly scaled the ongoing partnership due to JM鈥檚 track-record in high potency GMP manufacturing and proven chemical and analytical development for scale-up and production of complex molecules.
鈥淲e are proud to build on our existing relationship with Immunomedics to enable the production of viable treatment options to improve cancer patients鈥� lives,鈥� said Nick Shackley, Vice President, Health. 鈥淭his long-term master supply agreement signifies our continuing dedication to help companies deliver novel treatments and medicines, to create a healthier world.鈥�